Quality of Life and Cognitive Functioning as Prognostic Factor in Glial Tumours
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Change in Quality of Life Score (EORTC QLQ-C30 and QLQ-BN20)
研究概览
简要总结
The aim of this study is to introduce appropriate assessment instruments and to define patients with gliomas according to cognitive functioning and quality of life. The study will evaluate cognitive functioning as a prognostic factor for survival in patients with glial tumors and will support optimization of treatment strategies to improve patients' quality of life.
详细描述
This prospective cohort study will assess cognitive functioning and quality of life in patients with glial tumors. The objective is to determine the prognostic value of cognitive functioning on survival, establish appropriate assessment instruments, and contribute to treatment adaptation with the goal of improving quality of life in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult participants (≥18 years)
- •Patients with histologically confirmed glial tumour
- •Ability to understand the study procedures and provide written informed consent
- •Ability to complete quality of life questionnaires and cognitive testing
排除标准
- •Age <18 years
- •Inability to provide informed consent
- •Severe cognitive impairment or clinical condition preventing completion of questionnaires and cognitive testing
- •Insufficient language proficiency to complete the questionnaires and neuropsychological testing
研究组 & 干预措施
Glioma Patients
Patients with glial tumors assessed for quality of life and cognitive functioning as prognostic factors.
干预措施: Cognitive Functioning and Quality of Life Assessment (Other)
结局指标
主要结局
Change in Quality of Life Score (EORTC QLQ-C30 and QLQ-BN20)
时间窗: Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months
Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer questionnaires EORTC QLQ-C30 and the brain cancer module EORTC QLQ-BN20. Scores range from 0 to 100 points. The outcome will be reported as mean change in questionnaire score (points) from baseline to each follow-up assessment.
次要结局
- Change in Cognitive Function Test Performance (Neuropsychological Test Battery)(Baseline (before treatment); 6 weeks; 3 months; 6 months; 12 months)